EPIGENESIS PHARMACEUTICALS

Serial Number 78355970
606

Registration Progress

Application Filed
Jan 22, 2004
Under Examination
Sep 27, 2005
Approved for Publication
Jun 15, 2005
Published for Opposition
Jul 5, 2005
Registered

Trademark Image

EPIGENESIS PHARMACEUTICALS

Basic Information

Serial Number
78355970
Filing Date
January 22, 2004
Published for Opposition
July 5, 2005
Abandonment Date
October 27, 2008
Drawing Code
3000

Status Summary

Current Status
Inactive
Status Code
606
Status Date
Oct 27, 2008
Classes
005

Rights Holder

EPIGENESIS PHARMACEUTICALS LLC

03
Address
2009 Eastpack Boulevard
CRANBURY, NJ 08512

Ownership History

EPIGENESIS Pharmaceuticals, Inc.

Original Applicant
03
Cranbury, NJ

EPIGENESIS PHARMACEUTICALS LLC

New Owner Before Publication #1
03
CRANBURY, NJ

EPIGENESIS PHARMACEUTICALS LLC

Owner at Publication
03
CRANBURY, NJ

Legal Representation

Attorney
Albert P. Halluin

USPTO Deadlines

All Deadlines Cleared

All 3 deadline(s) have been cleared by subsequent events. No active deadlines at this time.

Application History

32 events
Date Code Type Description Documents
Oct 27, 2008 ABN6 S ABANDONMENT - NO USE STATEMENT FILED Loading...
Oct 27, 2008 MAB6 O ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED Loading...
Apr 4, 2008 EX5G S SOU EXTENSION 5 GRANTED Loading...
Mar 14, 2008 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Mar 14, 2008 EXT5 S SOU EXTENSION 5 FILED Loading...
Sep 26, 2007 EX4G S SOU EXTENSION 4 GRANTED Loading...
Sep 13, 2007 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Sep 13, 2007 EXT4 S SOU EXTENSION 4 FILED Loading...
Jun 28, 2007 EX3G S SOU EXTENSION 3 GRANTED Loading...
Mar 20, 2007 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Mar 20, 2007 EXT3 S SOU EXTENSION 3 FILED Loading...
Oct 24, 2006 EX2G S SOU EXTENSION 2 GRANTED Loading...
Sep 22, 2006 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Sep 22, 2006 EXT2 S SOU EXTENSION 2 FILED Loading...
Apr 28, 2006 EX1G S SOU EXTENSION 1 GRANTED Loading...
Mar 24, 2006 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Mar 24, 2006 EXT1 S SOU EXTENSION 1 FILED Loading...
Sep 27, 2005 NOAM O NOA MAILED - SOU REQUIRED FROM APPLICANT Loading...
Jul 5, 2005 PUBO A PUBLISHED FOR OPPOSITION Loading...
Jun 15, 2005 NPUB O NOTICE OF PUBLICATION Loading...
Mar 28, 2005 PREV O LAW OFFICE PUBLICATION REVIEW COMPLETED Loading...
Mar 25, 2005 ALIE A ASSIGNED TO LIE Loading...
Mar 18, 2005 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Mar 17, 2005 ACEC I AMENDMENT FROM APPLICANT ENTERED Loading...
Jan 31, 2005 MAIL I PAPER RECEIVED Loading...
Jan 31, 2005 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Oct 5, 2004 TCCA I TEAS CHANGE OF CORRESPONDENCE RECEIVED Loading...
Aug 21, 2004 GNRT F NON-FINAL ACTION E-MAILED Loading...
Aug 12, 2004 DOCK D ASSIGNED TO EXAMINER Loading...
Jul 20, 2004 PARI I TEAS VOLUNTARY AMENDMENT RECEIVED Loading...
Jul 16, 2004 MAIL I PAPER RECEIVED Loading...
Feb 2, 2004 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Medical diagnostic and therapeutic preparations, all for administration via diverse routes of administration including through the respiratory airways, and, medical devices for administering the pharmaceuticals, sold filled, the preparations including nucleotides, proteins and organic molecules for medical use, including macromolecules such as anti-sense oligonucleotides and enzymes and small and inorganic molecules for treatment of human and non-human animal respiratory, central nervous system, neoplastic, endocrine, immune and cardiovascular ailments, including bronchoconstriction, difficult breathing, impeded and obstructed lung airways, allergy(ies) and/or inflammation, which in some cases are adenosine receptor associated symptoms; pharmaceutical preparations for testing, and preventing and therapeutically treating respiratory, airway and pulmonary diseases and conditions, such as asthma, pulmonary vasconconstriction, inflammation, allergies, impeded respiration, acute respiratory disease syndrome (ARDS), renal damage and failure, ischemia resulting from the administration of certain drugs, including adenosine and other drugs for, for example, treating supra ventricular tachycardia (SVT), adenosine stress tests, infantile respiratory distress syndrome (infantile RDS), pain, cystic fibrosis, allergic rhinitis, allergic bronchitis, pulmonary hypertension, pulmonary vasconcontriction, emphysema, chronic obstructive pulmonary disease (COPD), as well as cancers including leukemias, lymphomas, carcinomas, and the like, eg colon cancer, breast cancer, lung cancer, pancreatic cancer, hepatocellular carcinoma, kidney cancer, melanoma, etc, as well as metastatic cancers, eg, cancers which metastasized to the lung(s), breast, liver and prostate
First Use Anywhere: 0
First Use in Commerce: 0

Additional Information

Color Claim
Color is not claimed as a feature of the mark.

Classification

International Classes
005

Disclaimers

The following terms have been disclaimed and are not claimed as part of the trademark:
General Disclaimer
PHARMACEUTICALS